(1-Bromo-1,1-difluoronon-2-yn-4-yl) acetate | 1042744-10-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1-Bromo-1,1-difluoronon-2-yn-4-yl) acetate
• CAS: 1042744-10-4
• 化学式: C₁₁H₁₅BrF₂O₂
• 分子量: 297.14
• InChiKey: OXHPWUBPMQZNOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• THERAPEUTIC COMPOUNDS
  申请人：Hammond Gerald B.

  公开号：US20080188570A1

  公开（公告）日：2008-08-07

  The invention provides compounds of Formula (I): wherein R 1 and R 2 have any of the values or specific values defined herein, as well as compositions comprising such compounds and therapeutic methods comprising the administration of such compounds.

  本发明提供了式(I)的化合物： 其中R1和R2具有任意的或特定的定义值，以及包含这些化合物的组合物和包括这些化合物给药的治疗方法。
• PREDICTIVE MARKER OF DNMT1 INHIBITOR THERAPEUTIC EFFICACY AND METHODS OF USING THE MARKER
  申请人：Bates Paula J.

  公开号：US20140329911A1

  公开（公告）日：2014-11-06

  Provided herein are methods for predicting efficacy of a DNA (cytosine-5)-methyltransferase 1 (DNMT1) inhibitor treatment in a subject having a cancer, methods of identifying a subject having a cancer that is more likely to respond to a DNMT1 inhibitor treatment, and methods of selecting a treatment for a subject having a cancer that include determining a level of SOX9 in a sample containing cells from a subject having a cancer. Also provided are methods of treating a subject having a cancer that include selectively administering a DNMT1 inhibitor to a subject having cancer determined to have an elevated level of SOX9 in a sample containing cells from the subject compared to a reference level. Also provided are antibodies and antigen-binding antibody fragments that specifically bind to SOX9, and nucleic acid sequences that contain at least 10 nucleotides complementary to a contiguous sequence present in a SOX9 nucleic acid for use in these methods.
• COMPOSITIONS AND METHODS FOR MODULATING DNMT1 INHIBITOR ACTIVITY
  申请人：UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.

  公开号：US20150238439A1

  公开（公告）日：2015-08-27

  Some aspects of the invention include attenuating DNMT1 inhibitor activity in an animal comprising administering an antioxidant. Other aspects of the invention include methods comprising administering a composition comprising a DNMT1 inhibitor and an antioxidant. In some instances in the methods, the animal is undergoing a treatment for cancer. Additional aspects of the invention include compositions comprising a DNMT1 inhibitor and an antioxidant.
• METHODS FOR TREATING DISEASES
  申请人：UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.

  公开号：US20200108050A1

  公开（公告）日：2020-04-09

  Some embodiments of the invention include methods of using a compound such as Formula (I), Formula (II), or I-1 (e.g., in compositions or in pharmaceutical compositions) for treating diseases (e.g., cancer such as chemo-resistant cancer or cancer-therapy-resistant cancer). Additional embodiments of the invention are also discussed herein.
• US8207381B2
  申请人：——

  公开号：US8207381B2

  公开（公告）日：2012-06-26